Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for severe and critical COVID-19
ChiCTR2000029762Phase 4Suspended
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Negative conversion rate of COVID-19 nucleic acid and Lung inflammation absorption ratio. Started Feb 2020; status: suspended.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029762.